Company Overview - The company, Vaimo Biotechnology (Zhejiang) Co., Ltd., focuses on the ophthalmology sector and aims to become a global leader in innovative ophthalmic therapies [4] - Established in 2016, the company has developed a competitive and differentiated product pipeline addressing various ophthalmic indications with significant unmet clinical needs [4] Core Products - VVN461 (High Dose) is a novel dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), currently undergoing Phase III clinical trials in China for non-infectious anterior uveitis (NIAU) [4][6] - VVN001 is a second-generation LFA-1 antagonist designed for treating dry eye disease (DED), with ongoing Phase III clinical trials in China [4][9] Clinical Development - VVN461 has shown comparable anti-inflammatory efficacy to corticosteroids in head-to-head Phase II trials, with a breakthrough therapy designation granted by the National Medical Products Administration (NMPA) [7] - VVN001 demonstrated higher efficacy and safety compared to the standard treatment cyclosporine A (CsA) in clinical trials, improving patient experience and compliance [10] Financial Information - For the nine months ending September 30, 2024, the company reported other income and gains of approximately RMB 8.572 million, with research and development expenses of about RMB 128.261 million [11] - The company incurred losses of approximately RMB 201.535 million for the fiscal year ending 2024 [12] Industry Overview - The global ophthalmic drug market is estimated to reach USD 41.6 billion in 2024, with a projected compound annual growth rate (CAGR) of 2.8% from 2024 to 2029, driven by an aging population and increasing prevalence of eye diseases [13] - The Chinese ophthalmic drug market is expected to grow from USD 2.7 billion in 2020 to USD 4.1 billion in 2024, with a CAGR of 10.8% [16]

智通财经APP获悉，据港交所2月13日披露，维眸生物科技(浙江)股份有限公司-B(简称：维眸生物)向港 交所主板递交上市申请书，中金公司为其独家保荐人。 | 纂]項下的[編纂]數目 | : [編纂]股H股(視乎[編纂] | | --- | --- | | | 行使與否而定) | | [編纂]數目 | : [編纂]股H股(可予車新分配) | | [編纂]數目 | : [编纂]股H股(可予重新分配及 | | | 視乎[編纂]行使與否而定) | | [編纂] | : 每股H股[編纂],另加1.0%經紀 | | | 佣金、0.0027%證監會交易徵費、 | | | 0.00565%聯交所交易費及0.00015% | | | 會財局交易徵費(須於申請時以港元 | | | 繳足,多繳股款可予退還) | | | . 气见工服 足散010元 | 公司简介 据招股书，该公司成立于2016年，是一家聚焦眼科领域的生物科技企业，致力于成为创新眼科疗法研发 与商业化领域的全球领军企业。依托该公司在眼科疾病小分子药物发现、高端制剂开发及转化医学研究 领域的专业技术积淀，该公司正打造具备竞争力且差异化的产品管线，覆盖眼表、眼底存在重大未 ...

Group 1 - The core viewpoint of the article is that Weimou Biotechnology (Zhejiang) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as its sole sponsor [1] - The company has two core products, VVN461 (high dose) and VVN001, with VVN461 being a novel dual-target inhibitor for Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) [1] - VVN461 (high dose) is a high-dose formulation of VVN461 eye drops, with potency reaching nanomolar levels [1] Group 2 - The company was established in 2016 and focuses on the ophthalmology sector, aiming to become a global leader in the development and commercialization of innovative ophthalmic therapies [4] - In addition to its core products, the company has six other candidate drugs, three of which are in clinical stages as of the last feasible date [1]

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of VivaVision Biotech (Zhejiang) Co., Ltd.* 維眸生物科技 (浙 江 )股份有限公司 (the "Compan ...

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 VivaVision Biotech (Zhejiang) Co., Ltd.* 維眸生物科技（浙江）股份有限公司 （「本公司」） （於中華人民共和國成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即表示 閣 下知悉、接納並向本公司、其獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公 司招股章程作出投資決定。招股章程的文本將於發售期內向公眾發佈。 * 僅供識別 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中 的資料作出任 ...

Fund Raising Events - Zhongke Chuangxing Leading Venture Capital Fund completed its first close with 2.617 billion yuan. 70% of the funds will be invested in early-stage hard technology projects, focusing on the "AI+" field [3] - Fujian Industrial Fund initiated and established its second specialized and sophisticated fund of the year, with a scale of 600 million yuan, supporting specialized and sophisticated SMEs in the new energy field [4] - Jiangsu Marine Economy Equity Investment Fund, with a scale of 2 billion yuan, is publicly selecting industrial sub - fund management institutions to support the development of marine strategic emerging industries in Jiangsu [5] Large - scale Financing - Zhongshu Ruizhi completed a 200 million yuan A+++ round of financing, with funds for R & D and market promotion to strengthen its position in AI intelligent agent infrastructure and industry implementation [6] - Weimou Biotech completed a 140 million yuan D2+ round of financing, focusing on R & D of ophthalmic innovative drugs [7] - CertifID completed a $47.5 million C - round of financing, using funds to expand product functions and strengthen its market leadership in wire transfer security [9] Policy Focus - Henan encourages listed companies to carry out mergers and acquisitions to transform and upgrade and gather resources in new productive forces fields [10] - Beijing aims to build an internationally influential "Quantum Constellation" new - quality industrial ecological community by 2027 [11]